64.4  -7.28 (-10.16%)		06-01 16:00
Open: 58.37 High: 65.23 Volume: 2,595,976		Pre. Close: 71.68 Low: 54.52 Market Cap: 2,764(M)

Short term
Mid term
Targets	6-month :	92.85	1-year :	108.45
Resists	First :	79.5	Second :	92.85
Pivot price	65.22
Supports	First :	60.74	Second :	49.15
MAs	MA(5) :	70.07	MA(20) :	63.78
	MA(100) :	68.4	MA(250) :	63.72
MACD	MACD :	3.8	Signal :	3.5
%K %D	K(14,3) :	58.8	D(3) :	73.7
RSI	RSI(14): 53
52-week	High :	118.83	Low :	29.95

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GRAL ] has closed above bottom band by 45.5%. Bollinger Bands are 26.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	65.3 - 65.65	65.65 - 65.95
Low:	53.78 - 54.16	54.16 - 54.48
Close:	63.72 - 64.41	64.41 - 64.98

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Mon, 01 Jun 2026
Galleri trial data and new CEO package at GRAIL (NASDAQ: GRAL) spotlight MCED progress - Stock Titan

Mon, 01 Jun 2026
GRAIL, Inc. (GRAL): One of the Best Stock Picks of Jeff Bezos - Insider Monkey

Mon, 01 Jun 2026
GRAIL, Inc. (GRAL): One of the Best Stock Picks of Jeff Bezos - Yahoo Finance

Mon, 01 Jun 2026
Grail (GRAL) Sees Significant Decline in Stock Price - GuruFocus

Mon, 01 Jun 2026
Grail (GRAL) Sees Significant Drop of 18.4% - GuruFocus

Mon, 01 Jun 2026
Grail stock tumbles 20% on mixed PATHFINDER 2 trial results - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	43 (M)
Shares Float	34 (M)
Held by Insiders	4.7 (%)
Held by Institutions	83.5 (%)
Shares Short	7,150 (K)
Shares Short P.Month	6,990 (K)

EPS	-10.31
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	60.79
Profit Margin	-253.3 %
Operating Margin	-332.9 %
Return on Assets (ttm)	-11.5 %
Return on Equity (ttm)	-16.1 %
Qtrly Rev. Growth	28.1 %
Gross Profit (p.s.)	1.79
Sales Per Share	3.63
EBITDA (p.s.)	-8.4
Qtrly Earnings Growth	0 %
Operating Cash Flow	-291 (M)
Levered Free Cash Flow	-108 (M)

PE Ratio	-6.26
PEG Ratio	0
Price to Book value	1.05
Price to Sales	17.7
Price to Cash Flow	-9.5

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.